Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Biotechnology

Healthcare
$7.38 -2.78%

-$0.15 today

Market cap
$2.10B
Beta
0.71
P/E (TTM)
-7.1
EPS (TTM)
-$0.71
52W Low $1.99High $5.32

Volume 1.41M

Average 2.42M

MRVI Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin widens to -29.3%

Operating margin was -29.3% in Q2 FY2026, up 110.5 pp from a year earlier. On a trailing-twelve-month basis it was 46.0%, up 195.5 pp year over year. Over 3 fiscal years it narrowed by 68.7 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 7 analysts of 13.9% for the fiscal year ending Dec 2026, up from -3.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-29.3%-33.1 pp QoQ
Last fiscal yearDec 2025
-3.6%+87.3 pp YoY
LTMJun 2026
46.0%+195.5 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+110.5 pp-290.2 pp-400.7 pp
1 year+87.3 pp+17.6 pp-69.7 pp
3 years-68.7 pp+17.3 pp+86.0 pp
5 years+16.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-3.6%
Year-over-year change
+87.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How MRVI compares with its peers on the latest reported figures

  • MRVI's LTM Jun 2026 operating margin of 46.0% is the highest of the 9 companies compared; the peer median is -5.9%.
  • Its year-over-year change of +195.5 pp is the 2nd highest of 9, against a peer median of -0.2 pp.
  • Over three fiscal years its change of -68.7 pp compares with a peer median of -6.9 pp.
MRVI Competitors Peer median
Operating Margin for MRVI and competitors
Company Period LTM level YoY 3-year change
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 202646.0% +195.5 pp-68.7 pp
TECHBio-Techne CorporationLTM Sep 202619.6% +10.6 pp-5.6 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 20269.1% +0.3 pp-6.8 pp
RGENRepligen CorporationLTM Jun 20268.3% +11.9 pp-20.0 pp
NEOGNeogen CorporationLTM Aug 2026-0.8% -0.8 pp-7.0 pp
BLFSBioLife Solutions, Inc.LTM Mar 2026-10.9% -3.8 pp+6.6 pp
AZTAAzenta, Inc.LTM Sep 2026-27.7% -26.6 pp-15.7 pp
LABStandard BioTools Inc.LTM Mar 2026-91.0% -2.5 pp+9.3 pp
PACBPacific Biosciences of California, Inc.LTM Mar 2026-101.7% +437.7 pp-109.0 pp
Peer median (excluding MRVI) -5.9%-0.2 pp-6.9 pp

Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue799.24M883M288.95M259.19M185.74M
Cost of Revenue140.56M168.96M148.74M150.88M152.35M
Gross Profit658.68M714.04M140.2M108.31M33.39M
Gross Margin82.4%80.9%48.5%41.8%18.0%
Research & Development15.22M18.37M17.28M19.22M23.33M
Selling, General & Admin100.06M129.26M151.39M161.77M171.47M
Operating Expenses104.03M139.83M171.85M343.93M40.13M
Depreciation & Amortization24.75M38.1M48.78M56.87M60.47M
EBITDA585.78M609.99M712.41M(156.92M)(147.51M)
EBITDA Margin73.3%69.1%246.6%-60.5%-79.4%
Operating Income554.65M574.22M(31.65M)(235.62M)(6.74M)
Operating Margin69.4%65.0%-11.0%-90.9%-3.6%
Interest Income02.34M27.73M27.4M23.95M
Interest Expense30.26M20.41M45.89M47.7M26.99M
Other Income / Expenses(23.88M)(22.74M)649.38M(25.87M)(228.24M)
Income Before Tax530.77M551.47M617.74M(261.48M)(234.97M)
Pre-Tax Margin66.4%62.5%213.8%-100.9%-126.5%
Income Tax Expense61.52M60.81M756.11M(1.86M)(4.21M)
Net Income182.04M220.21M(119.03M)(144.85M)(130.77M)
Net Margin22.8%24.9%-41.2%-55.9%-70.4%
EPS (Basic)1.591.67(0.90)(1.05)(0.91)
EPS (Diluted)1.561.67(0.90)(1.05)(0.91)
Weighted Avg Shares114.79M131.54M131.92M137.91M145.07M
Weighted Avg Shares (Diluted)121.97M131.7M131.92M137.91M145.07M

Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Intrinsic Alpha fair value

Locked

Current Price

$7.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.